Last reviewed · How we verify
Placebo for tanezumab
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in tanezumab phase 3 clinical trials for osteoarthritis pain.
At a glance
| Generic name | Placebo for tanezumab |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. In this context, it serves as the control arm in phase 3 trials of tanezumab, a nerve growth factor (NGF) inhibitor being developed for pain management. Any observed effects in placebo recipients are attributed to the placebo effect or natural disease progression.
Approved indications
- Control arm in tanezumab phase 3 clinical trials for osteoarthritis pain
Common side effects
- Placebo effect (symptom improvement without active drug)
Key clinical trials
- A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome (PHASE2)
- RN624 In Adult Patients With Chronic Low Back Pain (PHASE2)
- A Study of Tanezumab in Adults With Chronic Low Back Pain (PHASE2)
- Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip (PHASE3)
- A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone (PHASE2)
- RN624 For Pain Of Post-Herpetic Neuralgia (PHASE2)
- Tanezumab in Osteoarthritis of the Hip or Knee (2) (PHASE3)
- Tanezumab In Osteoarthritis Of The Knee (2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for tanezumab CI brief — competitive landscape report
- Placebo for tanezumab updates RSS · CI watch RSS
- Pfizer portfolio CI